Enhabit finalizes $1.1B acquisition deal, marking a pivotal moment in home health care

Enhabit, a leading home health and hospice provider, has completed its $1.1 billion sale to private equity firm Kinderhook Industries, ushering in a new chapter for the company after a two-year strategic review driven by investor demands. The all-cash transaction values Enhabit at $13.80 per share, with an implied multiple of 10x to its projected 2026 earnings, providing what analysts at Jefferies believe should satisfy investors.

Stability amid transformation

Despite the significant ownership shift, Enhabit’s CEO, Barb Jacobsmeyer, has assured that the company will maintain stability in its daily operations and strategic direction. In a written statement, Jacobsmeyer said, "Enhabit intends to continue operating as it does today, with the same leadership, strategy and commitment to our employees and communities. We do not anticipate any material changes to our day-to-day operations, team structure or the way we serve patients as a result of this transaction."

However, a notable leadership change is on the horizon: Jacobsmeyer previously announced her intention to step down in July 2026 or upon the appointment of her successor. Industry experts have suggested that this leadership transition and the sale are likely part of a coordinated effort to ensure a smooth evolution for the organization.

The stability highlighted by Jacobsmeyer underscores the strides Enhabit has made in recent years, following its spin-off from Encompass in 2022 and subsequent efforts to stabilize the business. These efforts are reflected in the company’s improved ability to navigate challenging industry conditions, including Medicare reimbursement uncertainty and shifting market dynamics.

sbb-itb-a3ef7c1

Kinderhook’s plans for growth

Kinderhook Industries brings extensive experience in the home health sector, positioning Enhabit for significant growth under its ownership. During Kinderhook’s tenure with Florida-based Trilogy Home Healthcare, the firm successfully scaled the provider through nine acquisitions, expanding its footprint to 11 offices. Kinderhook Managing Director Michael Michalik said, "We believe deeply in [the home health/hospice] model, and our track record proves it. Home health has been a core area of focus for Kinderhook for decades."

With Enhabit’s larger scale - 249 home health locations and 117 hospice facilities - Kinderhook’s strategy is expected to amplify the company’s growth potential. Michalik emphasized, however, that the approach to acquisitions will remain "thoughtful."

Joe Widmar, director of mergers and acquisitions at West Monroe, explained that Kinderhook’s involvement will likely accelerate Enhabit’s push into value-based arrangements, partnerships, technology advancements, and acquisitive growth. "These pushes won’t represent a radical change in the company’s operating model, but the speed at which the company can execute these goals is set to accelerate without the weight of a public stock market on its back", Widmar noted.

Alignment with industry trends

Enhabit’s dual focus on home health and hospice services aligns well with broader industry trends. Hospice services, in particular, continue to subsidize home health services, while also enhancing patient experiences and containing costs. The transition to value-based care is another priority, as home-based care providers seek to diversify their revenue streams amid persistent reimbursement challenges.

The company has made significant progress in this area. By the first quarter of 2025, nearly 44% of Enhabit’s non-Medicare visits were tied to payer innovation contracts, which focus on episodic reimbursement and quality-based arrangements rather than traditional per-visit rates. This shift is seen as essential for mitigating risks associated with fee-for-service Medicare reimbursement, which once accounted for 80% of the company’s revenue.

The deal also reflects changes in the broader M&A landscape. Analysts at Jefferies noted that recent regulatory and market developments, such as softened Medicare rate cuts for 2026 and a more stable interest rate environment, may have paved the way for this transaction. Additionally, private equity firms like Kinderhook are emerging as dominant players in the home health and hospice space, as exemplified by recent investments from firms such as Revelstoke, Linden Capital, and others.

A pivotal moment for home health care

As Kinderhook takes the reins, Enhabit is poised to leverage its scale, service lines, and payer innovation strategies to navigate an evolving home health care landscape. The deal highlights private equity’s growing influence in the sector and signals a shift toward platforms that prioritize value-based care, diversification, and strategic partnerships.

While transformation lies ahead, Enhabit’s emphasis on stability and thoughtful growth serves as a testament to the progress it has made since its spin-off. As Jacobsmeyer noted, the company remains committed to its mission to serve employees and communities, even as it embarks on this new chapter under Kinderhook’s ownership.

Read the source